Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Psychiatric Ratings using Intermediate Stratified Markers 2

Descripción del proyecto

Nuevos biomarcadores para la estratificación de trastornos neuropsiquiátricos

La clasificación de los trastornos neuropsiquiátricos, como la esquizofrenia, cuya base biológica es relativamente desconocida, se depende principalmente de biomarcadores de neuroimágenes y criterios de evaluación clínicos. El uso de biomarcadores cuantitativos no solo facilitaría la clasificación de las enfermedades, sino que también contribuiría al desarrollo de fármacos. El proyecto PRISM 2, financiado con fondos europeos, aprovechará los conocimientos obtenidos por su predecesor, el proyecto PRISM 1, sobre los biomarcadores de funcionamiento social y diagnóstico para la enfermedad de Alzheimer con el fin de ampliarlos a los principales trastornos depresivos. El objetivo es identificar biomarcadores fiables que contribuyan al diagnóstico y al tratamiento personalizado de trastornos neuropsiquiátricos.

Objetivo

The current nosology of neuropsychiatric disorders provides a pragmatic approach to diagnosis and treatment choice but lacks reference to quantitative biological underpinnings of disease. This weakness impedes innovative drug development. To test whether a quantitative biological approach to the understanding and classification of neuropsychiatric disorders is both feasible and useful the PRISM 1 consortium was formed by academics, SMEs, patient organizations, regulators, ECNP, and EFPIA partners. PRISM 1 has now successfully identified quantitative biological parameters related to diagnosis (Schizophrenia (SZ) and Alzheimer Disease (AD)) as well as to social functioning irrespective of diagnosis. From the relationships between social function, neuroimaging, and cognitive endpoints a new neurobiological framework has emerged now needing further validation. Genetic studies of social functioning outcomes revealed known and novel loci for this phenotype. In addition, a preclinical test battery was developed, based on homologs of the clinical paradigms, to allow effective back-translation and a deepening of our neurobiological knowledge. Finally, a novel digital tool for assessing social function provided a novel, objective characterization that transcended the initial diagnostic classification and the digital readouts were associated with other study parameters. To build on outcomes of PRISM 1, PRISM 2 has three objectives. First, to determine the reproducibility of the transdiagnostic and pathophysiological relationship between DMN integrity and social dysfunction in SZ and AD that emerged from PRISM 1 and determine its potential to generalise to Major Depressive Disorders. Second, to test the causality between the quantitative variation in DMN integrity and social dysfunction. Third, to translate and communicate project results to the benefit of stakeholders, such as regulators, patients and their families, and health care providers.

Régimen de financiación

RIA - Research and Innovation action

Coordinador

RIJKSUNIVERSITEIT GRONINGEN
Aportación neta de la UEn
€ 1 024 422,50
Dirección
Broerstraat 5
9712CP Groningen
Países Bajos

Ver en el mapa

Región
Noord-Nederland Groningen Overig Groningen
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 1 624 422,50

Participantes (17)